Based on our findings, N-terminal-bearing forms of tau seem to be secreted into CSF in an early phase of the Alzheimer’s disease pathological process, and like N-p-tau, N-t-tau biomarkers could provide added value in the variety of tau assays available for further research. This evidence concerns the gene MAPT and Alzheimer disease.